3rd Quarter - Report

VIATRIS INC. for VIATRIS INC

Firm
Client
Income
—
Expenses
$345,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Medicaid Generic Drug Rebate, Bipartisan Budget Act of 2015, H.R. 1314

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
NIMISH SHAH —

Contacted: White House Office; U.S. Trade Representative (USTR); SENATE; Program Support Center; HOUSE OF REPRESENTATIVES; Federal Trade Commission (FTC); Health & Human Services, Dept of (HHS)

Bills named: H.R. 1314 (114th)

Trade (domestic/foreign) TRD

Trans Pacific Partnership(TPP), TTIP (trans-atlantic trade and investment partnership agreement); General trade issues

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
NAWEL LILLIAN ROJKJAER —
NIMISH SHAH —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); White House Office; Health & Human Services, Dept of (HHS); Program Support Center; Federal Trade Commission (FTC)

Health Issues HCR

Issues related to epinephrine auto-injectors pricing Biosimilar Naming, Implementation of Food and Drug Administration Safety and Innovation Act (FDASIA) and Generic Drug User Fee Act (GDUFA), PL 112-144 Prescription drug pricing, Medicare Part D program and Generic Drugs HR 6, 21st Century Cures Act; Innovation for Healthier Americans Initiative; Issues regarding market exclusivity Drug Supply Chain Security Act implementation of pharmaceutical distribution REMs program, S. 3056 CREATES Act, H.R. 2841 FAST generics Act S. 2615 Increasing Competition in Pharmaceuticals Act, H.R. 4784 Lower Drug Costs through Competition Act, generic medicines pricing issues The Comprehensive Addiction and Recovery Act (CARA) S.524/H.R.953, the Addiction Prevention and Responsible Opioid Practices Act S.3075, Budgeting for CARA

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
MARCIE MCCLINTIC-COATES New —
MARC SCHLOSS —
NIMISH SHAH —

Contacted: Federal Trade Commission (FTC); Program Support Center; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); SENATE; White House Office

Bills named: H.R. 6 (114th), H.R. 4784 (114th), S. 524 (114th), H.R. 2841 (114th), H.R. 953 (114th), S. 2615 (114th), S. 3056 (114th), S. 3075 (114th)

Foreign entities

Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.

EntityCountryPrincipal place of businessOwnershipContribution declared
MYLAN NV United Kingdom United Kingdom 100.0% —
MYLAN HOLDINGS LIMITED United Kingdom United Kingdom 100.0% —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.